HIV infections Trials in Newark, United States
Conditions / HIV infections / Newark, United States
HIV infections has been the subject of sustained clinical investigation across multiple research sites.
237 total trials for this combination
Showing top 10 of 237 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01780506 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT01231516 | A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults | COMPLETED | PHASE3 |
| NCT01108510 | Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT00004978 | An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy | COMPLETED | PHASE3 |
| NCT01095796 | Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT01106586 | Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT00245739 | TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. | APPROVED_FOR_MARKETING | — |
| NCT00426660 | Expanded Access Program for Maraviroc At Multiple Centers | COMPLETED | PHASE3 |
| NCT01815736 | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants | COMPLETED | PHASE3 |
| NCT00000783 | Heterosexual HIV Transmission Study (HATS) | COMPLETED | — |